MX2021011746A - Formulacion de combinacion triple de dosis baja. - Google Patents

Formulacion de combinacion triple de dosis baja.

Info

Publication number
MX2021011746A
MX2021011746A MX2021011746A MX2021011746A MX2021011746A MX 2021011746 A MX2021011746 A MX 2021011746A MX 2021011746 A MX2021011746 A MX 2021011746A MX 2021011746 A MX2021011746 A MX 2021011746A MX 2021011746 A MX2021011746 A MX 2021011746A
Authority
MX
Mexico
Prior art keywords
inhibitor
low dose
combination formulation
triple combination
biguanide
Prior art date
Application number
MX2021011746A
Other languages
English (en)
Spanish (es)
Inventor
Anthony Rodgers
Stephen Macmahon
Original Assignee
The George Inst For Global Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The George Inst For Global Health filed Critical The George Inst For Global Health
Publication of MX2021011746A publication Critical patent/MX2021011746A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2021011746A 2019-03-25 2020-03-25 Formulacion de combinacion triple de dosis baja. MX2021011746A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/364,063 US11033544B2 (en) 2019-03-25 2019-03-25 Low-dose triple combination formulation
PCT/IB2020/000214 WO2020194052A1 (en) 2019-03-25 2020-03-25 Low-dose triple combination formulation

Publications (1)

Publication Number Publication Date
MX2021011746A true MX2021011746A (es) 2021-10-22

Family

ID=72606637

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021011746A MX2021011746A (es) 2019-03-25 2020-03-25 Formulacion de combinacion triple de dosis baja.
MX2024013504A MX2024013504A (es) 2019-03-25 2021-09-24 Formulacion de combinacion triple de dosis baja

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024013504A MX2024013504A (es) 2019-03-25 2021-09-24 Formulacion de combinacion triple de dosis baja

Country Status (11)

Country Link
US (5) US11033544B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946344A4 (cg-RX-API-DMAC7.html)
JP (1) JP7586830B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004027A (cg-RX-API-DMAC7.html)
CN (2) CN113924096A (cg-RX-API-DMAC7.html)
AU (2) AU2020247542A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021018994A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134800A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021011746A (cg-RX-API-DMAC7.html)
TW (2) TW202102209A (cg-RX-API-DMAC7.html)
WO (1) WO2020194052A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation
KR102853692B1 (ko) * 2021-07-08 2025-09-02 한미약품 주식회사 시타글립틴, 다파글리플로진 및 메트포르민을 포함하는 경구용 복합정제
EP4415723A4 (en) * 2021-10-12 2025-09-03 Unison Pharmaceuticals Pvt Ltd PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF SITAGLIPTIN AND EMPAGLIFLOZIN
TR2023001202A1 (tr) * 2023-02-02 2024-08-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇lm kapli empagliflozin ve metformin hi̇droklorür tabletleri̇
KR20260000968A (ko) * 2024-06-26 2026-01-05 주식회사 종근당 제2형 당뇨병 치료용 조성물, 조합물 및 병용 요법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
MX339194B (es) * 2009-02-13 2016-05-16 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
US20170135981A1 (en) * 2014-05-16 2017-05-18 Astrazeneca Ab Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor
WO2016040462A2 (en) * 2014-09-09 2016-03-17 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation

Also Published As

Publication number Publication date
BR112021018994A2 (pt) 2022-02-08
CN119607213A (zh) 2025-03-14
JP7586830B2 (ja) 2024-11-19
EP3946344A4 (en) 2022-12-28
WO2020194052A1 (en) 2020-10-01
US20220226317A1 (en) 2022-07-21
CN113924096A (zh) 2022-01-11
AU2025226705A1 (en) 2025-09-25
MX2024013504A (es) 2024-12-06
US20220226315A1 (en) 2022-07-21
US11033544B2 (en) 2021-06-15
JP2022529208A (ja) 2022-06-20
US20220226316A1 (en) 2022-07-21
US20210260056A1 (en) 2021-08-26
AU2020247542A1 (en) 2021-11-11
TW202545526A (zh) 2025-12-01
TW202102209A (zh) 2021-01-16
CA3134800A1 (en) 2020-10-01
KR20220004027A (ko) 2022-01-11
US20200306246A1 (en) 2020-10-01
EP3946344A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
MX2024013504A (es) Formulacion de combinacion triple de dosis baja
CL2023003489A1 (es) Análogos triazolo-pirimidina para tratamiento de enfermedades relacionadas con inhibición helicasa recq del síndrome de werner
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
MX2021011745A (es) Formulacion de combinacion triple baja en dosis.
CL2023000167A1 (es) Péptidos funcionalizados como agentes antivirales
ECSP21080740A (es) Inhibidores del inflamasoma nlrp3
MX2021004431A (es) Procesos novedosos.
GEAP202316298A (en) Highly active compounds against covid-19
PE20240881A1 (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t
MX2019012884A (es) Terapia de combinacion.
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
NO20091938L (no) 7,8-dihydro-1,6-naftyridin-5(6H)-oner og relaterte bicykliske forbindelser som inhibitorer av dipeptidyl-peptidaser IV og metoder
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
MX2019011606A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900119A (es) Derivados de indolina sustitudos como inhibidores de la replicación vírica de dengue
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
ZA202210355B (en) Compositions and therapeutic uses of cannabidiol
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
AR132497A1 (es) Combinación de obicetrapib amorfo e inhibidor de sglt2